From cancer-cell-skills
Assesses whether a molecular/translational oncology study fits Cancer Cell journal scope based on mechanistic depth and translational relevance. Does not design experiments or edit prose.
How this skill is triggered — by the user, by Claude, or both
Slash command
/cancer-cell-skills:cc-scope-fitThe summary Claude sees in its skill listing — used to decide when to auto-load this skill
- Starting a project and unsure if Cancer Cell is the right venue
Cancer Cell publishes mechanistic, hypothesis-driven cancer biology and translational oncology. The recurring acceptance pattern combines two pillars:
In-scope topics include tumor biology and signaling, cancer genetics / genomics, the tumor microenvironment, immuno-oncology, metastasis, therapy resistance, and clinical-translational studies that carry mechanistic insight.
| Signal in the manuscript | Fit verdict |
|---|---|
| Clear mechanism + validated in cells, in vivo, AND human/patient data | Strong fit |
| Mechanism + in vivo, human data is associative but supportive | Likely fit — strengthen human anchor |
| Mechanism only in cell lines, no in vivo, no human relevance | Off-fit — go back to cc-study-design |
| Descriptive omics / atlas with no mechanism or vulnerability | Off-fit unless reframed around a mechanism |
| Strong clinical correlation but no mechanism | Off-fit — likely a specialty / clinical journal |
| Methods / tool paper without a cancer-biology discovery | Off-fit — a methods journal |
| Therapeutic claim with only in vitro support | Premature — needs in vivo / human validation |
For a borderline paper, reduce the decision to three evidence questions before investing in a full Cancer Cell package:
| Question | Strong answer | Weak answer |
|---|---|---|
| Mechanism | The causal molecular axis is perturbed, rescued, and connected to phenotype. | The axis is inferred from correlation or omics enrichment only. |
| Human anchor | Patient samples, clinical dataset, organoid, or translational model supports relevance. | Only immortalized cell-line evidence or an anecdotal clinical correlation. |
| Therapeutic/biomarker logic | The intervention, vulnerability, or stratification claim follows from the mechanism. | Translational language is aspirational and not tested. |
If one column is weak, the best next move is usually cc-study-design, not cover-letter polish. If all
three are strong, a presubmission inquiry can emphasize the mechanism, the human anchor, and the exact
delta over the nearest Cancer Cell or Cell Press papers.
【Scope verdict】Strong fit / Likely fit / Off-fit
【Mechanism (1 sentence)】...
【Orthogonal validation present】cells / in vivo / human — list which
【Translational hook】... (and whether evidence supports it)
【Gap vs. closest prior work】...
【Next step】Strengthen via cc-study-design / proceed to cc-study-design / reconsider venue
npx claudepluginhub brycewang-stanford/awesome-journal-skills --plugin cancer-cell-skillsEvaluates whether a cancer-biology manuscript fits Cancer Cell's scope, mechanistic depth, and translational-evidence bar. Helps frame submissions, differentiate from similar journals, and avoid desk-reject patterns.
Evaluates whether a study meets Cell's bar for a complete, mechanistic, hypothesis-driven story with converging evidence. Routes to the correct Cell Press venue (Cell, Molecular Cell, Cell Reports, Cell Reports Medicine) based on scope and significance.
Evaluates whether a clinical-oncology review or perspective fits Nature Reviews Clinical Oncology, covering commissioned-review expectations, topic-proposal route, and desk-reject heuristics.